As president of Blue Thorn Inc. health care consulting, Terry McInnis sets strategy, formally speaking or leading engagements at more than 100 companies and health systems ranging from universities to analytic firms, health plans and pharmaceutical manufacturers. Previously, as business lead for value-based care at LabCorp, Terry set the strategy and built internal capabilities to execute and partner with providers to align diagnostic analytics and clinical trials with better outcomes and lower costs. Co-author of the article highlighting the $528 billion U.S. spend on non-optimized drug therapy, she is a nationally recognized expert in medication management and successful drug cost/value strategies. She is passionate about the GTMRx Institute’s effort to ensure all patients have optimized medication use to vastly improve outcomes and reduce total cost of care.
Terry’s 30 years of experience spans practice, executive, and consulting roles. She previously served as chief transformation officer, CHESS; senior consultant, SSB Solutions; medical director for policy and government affairs, GlaxoSmithKline; corporate medical director, Michelin North America; and associated medical director and benefits manager, GE Power Systems. Her military health roles include chief of flight medicine at Patrick Air Force Base and four years on active duty during Operation Desert Shield and Operation Desert Storm.
Terry earned her bachelor’s degree from Erskine College and her medical degree from Wake Forest Medical School, where she was designated a National Institutes of Health student clinical scholar. She completed a residency in occupational medicine and her MPH at the University of Oklahoma. She is board certified in preventive and occupational medicine, a Fellow of the American College of Occupational and Environmental Medicine, a certified physician executive and a former course advisor to the department of continuing education of Harvard University. She currently serves as a director on the Board of Pharmacy Specialties.
Read Terry’s statement, “Why I Support the GTMRx Institute”
Access the research paper by Jonathan Watanabe, Pharm.D., M.S., Ph.D. BCGP, Terry McInnis, MD, MPH and Jan Hirsch, BS Pharm, Ph.D., Cost of Prescription Drug-Related Morbidity and Mortality.
“$528 billion spent on non-optimized drug therapy is heartbreaking- these are people’s lives and the result of a splintered, uncoordinated system.
Everybody is looking for solutions. When you consider that 85% of the means by which we prevent illness and control disease is with medications, this has to be a focal point to improve health care.
We’re at this critical juncture where scientific knowledge is not being translated quickly enough into clinical practice. We’re on the cusp of the movement from population health to precision medicine. We can increase the speed of that if we all come together and map the path to effective use of medications.”